Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?

References

• Comi G, Radaelli M, Soelberg Sørensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389:1347–1356.
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138:1863–1874.
   PubMed Web of Science ®Google Scholar
• Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-β in a multicenter dataset of patients with MS. Neurology. 2016;87:134–140.
   PubMed Web of Science ®Google Scholar
• Romeo MAL, Martinelli V, Dalla Costa G, et al. Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. Acta Neurol Scand. 2018;138:447–453.
   PubMed Web of Science ®Google Scholar
• Río J, Rovira A, Tintoré M, et al. Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. Mult Scler J. 2018;24:322–330.
   PubMedGoogle Scholar
• Tur C, Kalincik T, Oh J, et al. Head-to-head drug comparisons in multiple sclerosis: urgent action needed. Neurology. 2019;93:793–799.
   PubMed Web of Science ®Google Scholar
• Hla T, Lee MJ, Ancellin N, et al. Lysophospholipids–receptor revelations. Science. 2001;294:1875–1878.
   PubMed Web of Science ®Google Scholar
• Colombo E, Di Dario M, Capitolo E, et al. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann Neurol. 2014;76:325–337.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362: 387–01.
   Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–556.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415.
   PubMed Web of Science ®Google Scholar
• Barkhof F, de Jong R, Sfikas N, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in trial assessing injectable interferon vs FTY720 oral in relapsing-remitting multiple sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler. 2014;20:1704–1713.
   PubMed Web of Science ®Google Scholar
• Comi G, Patti F, Rocca MA, et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol. 2017;264:2436–2449.
   PubMed Web of Science ®Google Scholar
• Kappos L, O’Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84:1582–1591.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87:468–475.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Lang M, Tackenberg B, et al. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurol Neuroimmunol Neuroinflamm. 2019;6:e548.
   PubMed Web of Science ®Google Scholar
• Patrucco L, Cristiano E, Sánchez F, et al. Real-world effectiveness and safety of fingolimod in patients with relapsing remitting multiple sclerosis: a prospective analysis in Buenos Aires, Argentina. Clin Neuropharmacol. 2019;42:163–166.
   PubMed Web of Science ®Google Scholar
• Ceccarelli A, Mifsud V, Abusamra E, et al. Short term real-world Fingolimod efficacy and safety in Emirati patients with multiple sclerosis. J Clin Neurosci. 2020;71:39–42.
   PubMed Web of Science ®Google Scholar
• Alroughani R, Ahmed SF, Behbehani R, et al. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait. Clin Neurol Neurosurg. 2014;119:17–20.
   PubMed Web of Science ®Google Scholar
• Totaro R, Di Carmine C, Costantino G, et al. Fingolimod treatment in relapsing-remitting multiple sclerosis patients: a prospective observational multicenter postmarketing study. Mult Scler Int. 2015;763418.
   PubMed Web of Science ®Google Scholar
• Walczak A, Kurkowska-Jastrzebska I, Zakrzewska-Pniewska B, et al. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg. 2019;184:105453.
   PubMed Web of Science ®Google Scholar
• Correia I, Batista S, Marques IB, et al. The effectiveness of fingolimod in a Portuguese real-world population. Mult Scler Relat Disord. 2016;6:41–48.
   PubMed Web of Science ®Google Scholar
• Barrero F, Mallada-Frechin J, Martínez-Ginés ML, et al. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. PLoS One. 2020 Apr 2;15:e0230846.
   PubMed Web of Science ®Google Scholar
• Rasenack M, Rychen J, Andelova M, et al. Efficacy and safety of fingolimod in an unselected patient population. PLoS One. 2016;11:e0146190.
   PubMed Web of Science ®Google Scholar
• Vieira MC, Conway D, Cox GM, et al. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study. Curr Med Res Opin. 2020;36(2):261–270.
   PubMed Web of Science ®Google Scholar
• Hersh CM, Hara-Cleaver C, Rudick RA, et al. Experience with fingolimod in clinical practice. Int J Neurosci. 2015;125:678–685.
   PubMed Web of Science ®Google Scholar
• Baldi E, Guareschi A, Vitetta F, et al. Previous treatment influences fingolimod efficacy in relapsing-remittingmultiple sclerosis: results from an observational study. Curr Med Res Opin. 2014;30:1849–1855.
   PubMed Web of Science ®Google Scholar
• Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 2014;71(4):436-441.
   Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin. 2013;29:1647–1656.
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One. 2014;9:e88472.
   PubMed Web of Science ®Google Scholar
• He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. 2015;72:405–413.
   PubMed Web of Science ®Google Scholar
• Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82:1204–1211.
   PubMed Web of Science ®Google Scholar
• Braune S, Lang M, Bergmann A, et al. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. J Neurol. 2016;263:327–333.
   PubMed Web of Science ®Google Scholar
• Lo Re M, Capobianco M, Ragonese P, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurol Ther. 2015;4:147–157.
   PubMed Web of Science ®Google Scholar
• Iaffaldano P, Lucisano G, Pozzilli C, et al. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 2015;138:3275–3286.
   PubMed Web of Science ®Google Scholar
• Capobianco M, Di Sapio A, Malentacchi M, et al. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol. 2015;22:585–587.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Lucchini M, Haggiag S, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis: a real-world propensity score-matched study. Neurology. 2018;91:e153–e161.
   PubMed Web of Science ®Google Scholar
• Bergvall N, Lahoz R, Reynolds T, et al. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin. 2014;30:1461–1471.
   PubMed Web of Science ®Google Scholar
• Braune S, Lang M, Bergmann A, et al. Second-line use of fingolimod is as effective as natalizumab in a German out-patient RRMS-cohort. J Neurol. 2013;260:2981–2985.
   PubMed Web of Science ®Google Scholar
• Totaro R, Costantino G, Bellantonia P, et al. Efficacy of natalizumab and fingolimod in relapsing–remitting multiple sclerosis in real-world clinical setting. J Neurol Neurophysiol. 2016;6:1–6.
   Google Scholar
• Carruthers RL, Rotstein DL, Healy B, et al. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014;20:1381–1390.
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Bianchi MR, Deotto L, et al. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing–remitting multiple sclerosis? A clinical practice observational study. Eur Neurol Rev. 2014;72:173–180.
   Google Scholar
• Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015;77:425–435.
   PubMed Web of Science ®Google Scholar
• Barbin L, Rousseau C, Jousset N, et al. Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study. Neurology. 2016;86:771–778.
   PubMed Web of Science ®Google Scholar
• Al-Hashel J, Ahmed SF, Behbehani R, et al. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait. CNS Drugs. 2014;28:817–824.
   PubMed Web of Science ®Google Scholar
• Alroughani R, Ahmed SF, Behbehani R, et al. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait. Clin Neurol Neurosurg. 2014;119:17–20.
   PubMed Web of Science ®Google Scholar
• Bianco A, Patanella AK, Nociti V, et al. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab. Eur Neurol Rev. 2015;73:57–65.
   Google Scholar
• Yamout BI, Zeineddine MM, Sawaya RA, et al. Safety and efficacy of reduced fingolimod dosage treatment. J Neuroimmunol. 2015;285:13–15.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Medin J, Khan N, et al. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: a retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. Mult Scler Relat Disord. 2019 Jan;27:65–73.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Haase R, Proschmann U, et al. Real world lab data: patterns of lymphocyte counts in fingolimod treated patients. Front Immunol. 2018 Nov 20;9:2669.
   PubMed Web of Science ®Google Scholar
• Boffa G, Bruschi N, Cellerino M, et al. Fingolimod and dimethyl-fumarate-derived lymphopenia is not associated with short-term treatment response and risk of infections in a real-life MS population. CNS Drugs. 2020;34:425–432.
   PubMed Web of Science ®Google Scholar
• Zecca C, Merlini A, Disanto G, et al. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: observational study. Mult Scler. 2018 Feb;24(2):167–174.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Hara-Cleaver C, Rudick RA, et al. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;15:167–172.
   Google Scholar
• Lattanzi S, Danni M, Taffi R, et al. Persistence to oral disease-modifying therapies in multiple sclerosis patients. J Neurol. 2017;264:2325–2329.
   PubMed Web of Science ®Google Scholar
• Johnson KM, Zhou H, Lin F, et al. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23:844–852.
   PubMedGoogle Scholar
• Bergvall N, Petrilla AA, Karkare SU, et al. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J Med Econ. 2014;17:696–697.
   PubMedGoogle Scholar
• Berger JR, Cree BA, Greenberg B, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018;90:e1815–e21.
   PubMed Web of Science ®Google Scholar
• Nakahara J, Tomaske L, Kume K, et al. Three cases of non-carryover fingolimod-PML: is the risk in Japan increased? Neurol Neuroimmunol Neuroinflamm. 2019 Apr 10;6:e559.
   PubMed Web of Science ®Google Scholar
• Samudralwar RD, Spec A. Cross AH case report: fingolimod and cryptococcosis: collision of immunomodulation with infectious disease. Int J MS Care. 2019;21:275–280.
   PubMedGoogle Scholar
• Alping P, Askling J, Burman J, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020;87:688–699.
   PubMed Web of Science ®Google Scholar
• Drug Approval Package: Aubagio (teriflunomide) Tablets NDA #202992”. U.S. Food and Drug Administration (FDA). 2012 Nov 5 cited 2020 Mar 1.
   Google Scholar
• “Aubagio EPAR”. European Medicines Agency (EMA). 2020 Feb 26 cited 2020 Mar 1.
   Google Scholar
• Chan A, De Seze J, Comabella M. Teriflunomide in patients with relapsing remitting forms of multiple sclerosis. CNS Drugs. 2016;30:41–51.
   PubMed Web of Science ®Google Scholar
• Li L, Liu J, Ringheim G, et al. The effects ot teriflunomide on lymphocytes subpopulations in human peripheral blood mononuclear cells. Mult Scler. 2011;17:S422.
   Web of Science ®Google Scholar
• Klotz L, Eschborn M, Lindner M, et al. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci Transl Med. 2019;11:eaao5563.
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–03.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–256.
   PubMed Web of Science ®Google Scholar
• Radue EW, Sprenger T, Gaetano L, et al. Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA. Neurol Neuroimmunol Neuroinflamm. 2017;4:e390.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705–716.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Oct 1]. Available from: http://products.sanofi.ca/en/aubagio-en.pdf
   Google Scholar
• Kallmann BA, Tiel-Wilck K, Kullmann JS, et al. Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019;12:1756286419835077.
   Web of Science ®Google Scholar
• Boz C, Terzi M, Özer B, et al. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2019;36:101376.
   PubMed Web of Science ®Google Scholar
• Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. Neurology. 2019;92:e1811–e1820.
   PubMed Web of Science ®Google Scholar
• Condé S, Moisset X, Pereira B, et al. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study. Eur J Neurol. 2019;26:460–467.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Zanghì A, Sciandra M, et al. Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. J Neurol. 2019;266:411–416.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Cortese A, Lucchini M, et al. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study. J Neurol. 2020;267:694–702.
   PubMed Web of Science ®Google Scholar
• Gobbi C, Achtnichts L, Derfuss T, et al. Real-world data from the TACO (Teriflunomide in relapsing remitting multiple sclerosis patients assessing clinical benefit and patient-reported outcomes) study. ECTRIMS. 2019;2019:P1371.
   Google Scholar
• Coyle PK, Khatri B, Edwards KR, et al. Teriflunomide real-world evidence: global differences in the phase 4 Teri-PRO study. Mult Scler Relat Disord. 2019;31:157–164.
   PubMed Web of Science ®Google Scholar
• de Seze J, Devy R, Planque E, et al. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study. ECTRIMS. 2019;2019:P1157.
   Google Scholar
• Lorefice L, Fenu G, Gerevini S, et al. PML in a person with multiple sclerosis: is teriflunomide the felon? Neurology. 2018;90:83–85.
   PubMed Web of Science ®Google Scholar
• Litjens NH, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004;4:22.
   PubMedGoogle Scholar
• Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol. 2015;130:279–295.
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678–692.
   PubMed Web of Science ®Google Scholar
• Fox R, Miller DH, Phillips T, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–1107.
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Amit Bar-Or A, et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020;13:1756286420915005.
   Web of Science ®Google Scholar
• Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2:103–118.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. J Neurol. 2014;261:1794–1802.
   PubMed Web of Science ®Google Scholar
• Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84:1145–1152.
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23:253–265.
   PubMed Web of Science ®Google Scholar
• Gold R, Giovanni G, Philips JT, et al. Overall safety and efficacy through 10 years of treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis. Presented at: ECTRIMS, Stockholm, Sweden; 2019, p. P1397
   Google Scholar
• Paolicelli D, Manni A, Iaffaldano A, et al. Efficacy and safety of oral therapies for relapsing-remitting multiple sclerosis. CNS Drugs. 2020;34:65–92.
   PubMed Web of Science ®Google Scholar
• Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2019 Nov 4;1352458519881761.DOI: 10.1177/1352458519881761
   Web of Science ®Google Scholar
• Mirabella M, Prosperini L, Lucchini M, et al. Safety and Efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real‐world study. CNS Drugs. 2018;32:963–970.
   PubMed Web of Science ®Google Scholar
• Mallucci G, Annovazzi P, Miante S, et al. Two-year real-efficacy, tolerability and safety of dimethyl fumarate in an Italian multicenter study. J Neurol. 2018;265:1850–1859.
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Moccia M, Palladino R, et al. Clinical predictors of dimethyl fumarate response in multiple sclerosis: a real-life multicentre study multiple sclerosis and related disorders. 2020 Feb;38:101871.
   Google Scholar
• Forsberg L, Falt A, Kagstrom S et al. Clinical effectiveness of dimethyl fumarate for patients treated at least 36 months. A Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE). ECTRIMS 09/11/19; 279007. p. P647.
   Google Scholar
• Alroughani R, Farouk S, Behbehani R, et al. Effectiveness and safety of dimethyl fumarate treatment in relapsing multiple sclerosis patients: real-world evidence. Neurol Ther. 2017;6:189–196.
   PubMed Web of Science ®Google Scholar
• Pandey K, Giles K, Balashov K, et al. Safety and Effectiveness of Delayed-release Dimethyl Fumarate Maintained Over 4 Years in Multiple Sclerosis Patients Treated in Routine Medical Practice ECTRIMS 09/11/19; 279009, p. P649
   Google Scholar
• Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate, and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(4):458–468.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101–111.
   PubMed Web of Science ®Google Scholar
• Hersh CM, Love TE, Bandyopadhyay A, et al. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017;3:2055217317715485.
   Google Scholar
• Vollmer B, Ontaneda D, Bandyopadhyay A, et al. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018;8:292–301.
   PubMedGoogle Scholar
• Vollmer B, Nair KV, Sillau SH, et al. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience. Mult Scler J Exp Transl Clin. 2017;3:2055217317725102.
   Google Scholar
• Guger M, Enzinger C, Leutmezer F, et al. Real-life use of oral disease-modifying treatments in Austria. Acta Neurol Scand. 2019;140(1):32–39.
   PubMed Web of Science ®Google Scholar
• Braune S, Grimm S, van Hövell P, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265:2980–2992.
   PubMed Web of Science ®Google Scholar
• Cutter G, Sormani MP, Betts M, et al. Comparative effectiveness of delayed-release dimethyl fumarate vs. other disease-modifying therapies in patients with multiple sclerosis: a network meta-analysis of real-world evidence ECTRIMS 09/13/19; 278594, p. P1394
   Google Scholar
• Moiola L, Esposito F, Di Cristinzi M, et al. Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis patients ECTRIMS Online Library. Moiola L. 2018 Oct 11;228:231977.
   Google Scholar
• Sejbaek T, Nielsen H, Penner, et al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J Neurol Neurosurg Psychiatry. 2019;90:1324–1330.
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Hagemeier J, Bergsland N, et al. Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study. Eur J Neurol. 2018;25:584–e36.
   PubMed Web of Science ®Google Scholar
• Zuco, et al. DMF for MS in real life: impact on cortical pathology ECTRIMS 09/13/19; 278557, p. P1355.
   Google Scholar
• Amato MP, Goretti B, Bresciamorra, et al. Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing-remitting multiple sclerosis. Neurol Sci. 2020. DOI:10.1007/s10072-020-04320-w.
   Web of Science ®Google Scholar
• Zipoli, et al. Effect of Delayed-release Dimethyl Fumarate on Cognition in Italian Patients With Relapsing-Remitting Multiple Sclerosis: The Phase 4 StarTec Study ECTRIMS 2018.
   Google Scholar
• Miclea A, Leussink VI, Hartung HP, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol. 2016;263(8):1626–1632.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clin Risk Manag. 2016;12:339–350.
   PubMed Web of Science ®Google Scholar
• Wicks P, Rasouliyan L, Katic B, et al. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. BMC Res Notes. 2016;9:434.
   PubMedGoogle Scholar
• Laplaud D, Casey R, Barbin L, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93:e635–e646.
   PubMed Web of Science ®Google Scholar
• Frank R, Ernst FR, Peri Barr P, et al. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Curr Med Res Opin. 2017;33:12.
   Web of Science ®Google Scholar
• Sejbaek T, Nybo M, Petersen T, et al. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42–46.
   PubMed Web of Science ®Google Scholar
• Linker RA, Haghikia A. Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Ther Adv Chronic Dis. 2016;7:198–207.
   PubMed Web of Science ®Google Scholar
• EMA European Medicines Agency. Updated recommendations to minimize the risk of the rare brain infection PML with Tecfidera [press release]. 2015. [cited 2020 Oct 1]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/10/news_detail_002423
   Google Scholar
• Medina S, Villarrubia N, Sainz de la Maza SS, et al. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. Mult Scler. 2018 Sep;24(10):1317-1327.
   Google Scholar
• Longbrake EE, Naismith RT, Parks BJ, et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin. 2015;1:2055217315596994.
   Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci USA. 2013;110:20200–20205.
   PubMed Web of Science ®Google Scholar
• Comi G, Arnold DL, Boyko AN, et al. Alemtuzumab improves clinical and MRI outcomes. Including slowing of brain volume loss in RRMS patients over 8 years: CARE-MS1 follow up (Topaz study). MSJ. 2018;(suppl P1235).
   Google Scholar
• Cooles FA, Anderson AE, Drayton T, et al. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies. Arthritis Res Ther. 2016;18:302.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston A. Product licences for alemtuzumab and multiple sclerosis. Lancet. 2014;383:867–868.
   PubMed Web of Science ®Google Scholar
• FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug lemtrada (Alemtuzumab). cited 2020 Jul 10. Biomedicines 2019, 7, 20 13 of 13. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm
   Google Scholar
• Decallonne B, Bartholome E, Delvaux V, et al. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg. 2018;118:153–159.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Castells MC, Burstein HJ et al. Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy. cited 2020 Jul 10. Available from: https://www.uptodate.com/contents/infusion-related-reactions-to-therapeutic-monoclonal-antibodies-used-for-cancer-therapy
   Google Scholar
• Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99:80–89.
   PubMed Web of Science ®Google Scholar
• Frau J, Coghe G, Lorefice L, et al. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol. 2019;266:1405–1411.
   PubMed Web of Science ®Google Scholar
• Di Ioia M, Di Stefano V, Farina D, et al. Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report from a single Italian center. Mult Scler Relat Disord. 2020;38:101504.
   PubMedGoogle Scholar
• Prosperini L, Annovazzi, Boffa L, et al. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. J Neurol. 2018;265:2851–2860.
   PubMed Web of Science ®Google Scholar
• Saccà F, Russo CV, Frau J, et al. A real-world study of Alemtuzumab in a cohort of Italian patients. ECTRIMS 2019 Online Library 09/13/19; 278628, p. P1428S.
   Google Scholar
• Hun K, Bayas A, Doerck S, et al. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. J Neurol. 2018;265:1521–1527.
   PubMed Web of Science ®Google Scholar
• Alcala C, Gascon F, Perez-Miralles F, et al. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Neurol. 2019;266:726–734.
   Web of Science ®Google Scholar
• Willis M, Pearson O, Illes Z, et al. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017;4:e320.
   PubMed Web of Science ®Google Scholar
• Malucchi S, Capobianco M, Re M L, et al. High-risk PML patients switching from natalizumab to alemtuzumab: an observational study. Neurol Ther. 2017;6:145–152.
   PubMed Web of Science ®Google Scholar
• Ziemssen, Robin White, Raimar Kern et al. TREAT-MS study of real-world effectiveness of alemtuzumab in RRMS patients in Germany: subgroup analysis by number of prior disease-modifying therapies ECTRIMS 2019 online library. Haase R. 09/12/19; 279348, p. P988.
   Google Scholar
• Boffa G, Lapucci C, Sbragia E, et al. Aggressive multiple sclerosis: a single center, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. Eur J Neurol. 2020;27:2047–2055.
   PubMed Web of Science ®Google Scholar
• Rigoni E, Singh-Curry V, Nandoskar A, et al. Alemtuzumab as induction versus escalation therapy: efficacy and adverse events in the real-world ECTRIMS online library. ECTRIMS 2019. 09/13/19; P1398.
   Google Scholar
• Moiola L, Zanetta C, Di Cristinzi M et al. Italian prospective multicenter observational study conducted in daily clinical practice in patients affected by RRMS with highly active disease, naïve to therapies, who start a treatment with alemtuzumab (ALEM-NAIVE) ECTRIMS online library. 10/11/18; 228739; P89.
   Google Scholar
• Frau J, Saccà F, Signori A, et al. Outcomes AFTER fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre Cohort study. J Neurol. 2019;266:2440–2446.
   PubMed Web of Science ®Google Scholar
• John N, Carroll A, Brownlee J, et al. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:1376–1378.
   PubMed Web of Science ®Google Scholar
• Simona Malucchi S, Capobianco M, Lo Re M, et al. High-risk PML patients switching from natalizumab to alemtuzumab: an observational study. Neurol Ther. 2017;6:145–152.
   PubMed Web of Science ®Google Scholar
• Margoni M, Rinaldi F, Miante S, et al. Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis. Mult Scler J Exp Transl Clin. 2019;5:2055217319875471.
   Google Scholar
• Riepl E, Pfeuffer S, Ruck T, et al. Alemtuzumab improves cognitive processing speed in active multiple sclerosis-a longitudinal observational study. Front Neurol. 2018;8:730.
   PubMed Web of Science ®Google Scholar
• Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2017;13:871–879.
   PubMed Web of Science ®Google Scholar
• Chinea A, Honeycutt WD, Miller T, et al. Effect of alemtuzumab infusions on vital signs: a prospective observational study in patients with relapsing-remitting multiple sclerosis. Int J MS Care. 2020;22:53–59.
   PubMedGoogle Scholar
• Rodríguez de Castro B, Pampín Sánchez R, Tembrás Martinez S, et al. Alemtuzumab for relapsing multiple sclerosis in clinical practice: a four-year retrospective one-center study. Int J Risk Saf Med. 2020 Mar 5. DOI:10.3233/JRS-191029.
   PubMed Web of Science ®Google Scholar
• Bianco A, Mari PV, Larici AR, et al. Alemtuzumab-induced lung injury in multiple sclerosis: learning from adversity in three patients. Mult Scler Relat Disord. 2020;37:101450.
   PubMed Web of Science ®Google Scholar
• Sheikh-Taha M, Corman LC. Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Mult Scler J. 2017;23:872–874.
   PubMed Web of Science ®Google Scholar
• Penkert H, Delbridge C, Wantia N. Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol. 2016;73:757–759.
   PubMed Web of Science ®Google Scholar
• Holmøy T, Von der Lippe H, Leegaard T. Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies. BMC Neurol. 2017;17:65.
   PubMed Web of Science ®Google Scholar
• Rau D, Lang M, Harth A. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis: report of two cases. Int J Mol Sci. 2015;16:14669–14676.
   PubMed Web of Science ®Google Scholar
• Clerico M, De Mercanti S, Artusi CA, et al. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler J. 2017;23:874–876.
   PubMed Web of Science ®Google Scholar
• Zmira O, Alex I, Halpern AI, et al. Efficacy and safety of alemtuzumab treatment in a real‐world cohort of patients with multiple sclerosis. Acta Neurol Belg. 2020 May 23. DOI:10.1007/s13760-020-01375-6.
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Investig. 2009;119:2052–2061.
   PubMed Web of Science ®Google Scholar
• Bertolotto A, Arroyo R, Celius EG, et al. Quality of life improves with alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients with or without autoimmune thyroid adverse events: post Hoc analysis of the CARE-MS studies. Neurol Ther. 2020. DOI:10.1007/s40120-020-00191-7.
   Web of Science ®Google Scholar
• Wehrum T, Beume LA, Stich O, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology. 2018;90:e601–e605.
   PubMedGoogle Scholar
• Azevedo CJ, Kutz C, Dix A, et al. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol. 2019;18:329–331.
   PubMed Web of Science ®Google Scholar
• Holmøy T, Fevang B, Olsen BA, et al. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res Notes. 2019;12:497.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Oct 1]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/lemtrada
   Google Scholar
• Comi G, Bar-Or A, Lassmann H, et al. The role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2020. (in press).
   PubMed Web of Science ®Google Scholar
• McGinley MP, Moss BP, Cohen JA. Safety of monoclonal antibodies for the treatment of multiple sclerosis. Expert Opin Drug Saf. 2017;16:89–100.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord. 2016;9:44–52.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
   PubMed Web of Science ®Google Scholar
• Arnold DL, Kappos L, Hauser SL, et al. Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Mult Scler. 2018;24:284–285.
   Google Scholar
• Hauser SL, Brochet B, Montalban X, et al. Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Mult Scler. 2018;24:285–286.
   Web of Science ®Google Scholar
• Hauser SL, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Mult Scler. 2018;24:697–698.
   Google Scholar
• Ocrevus EPAR”. European Medicines Agency (EMA). cited 2020 Apr 25.
   Google Scholar
• Ellwardt E, Rolfes L, Klein J, et al. Ocrelizumab initiation in patients with MS: a multicenter observational study. Neurol Neuroimmunol Neuroinflamm. 2020;7:e71.
   Web of Science ®Google Scholar
• Boyko OV, Choroshilova II, Petrov SV, et al. Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119:120–127.
   PubMedGoogle Scholar
• Levin SN, Ezuma C, Levine L, et al. Switching from natalizumab to ocrelizumab in patients with multiple sclerosis. Mult Scler. 2020 Jul 19;1352458520927631. DOI: 10.1177/1352458520927631. Epub ahead of print. PMID: 32552363.
   Web of Science ®Google Scholar
• Nylund M, Vuorinen T, Airas L. Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy. Mult Scler Relat Disord. 2020;42:102058.
   PubMed Web of Science ®Google Scholar
• Zappulo E, Buonomo AR, Saccà F, et al. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis. 2019;6:ofz445.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Carlini G, Acciarri MC, et al. Parvovirus B19 infection in a patient with multiple sclerosis treated with ocrelizumab. Acta Neurol Belg. 2020;120:231–232.
   PubMed Web of Science ®Google Scholar
• Sunjaya DB, Taborda C, Obeng R, et al. First case of refractory colitis caused by ocrelizumab. Inflamm Bowel Dis. 2020;26:e49.
   PubMed Web of Science ®Google Scholar
• Novi G, Ivaldi F, Sbragia E, et al. Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS. Neurol Neuroimmunol Neuroinflamm. 2020;7:e695.
   PubMed Web of Science ®Google Scholar
• Faer S, Schwake C, Gotzmann M, et al. Endocarditis following ocrelizumab in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 3;7:e680.
   PubMed Web of Science ®Google Scholar
• Theriault M, Solomon AJ. Two cases of meningitis associated with ocrelizumab therapy. Mult Scler Relat Disord. 2020 Feb;38:101866.
   PubMed Web of Science ®Google Scholar
• Nicolini LA, Canepa P, Caligiuri P, et al. Fulminant hepatitis associated with echovirus 25 during treatment with ocrelizumab for multiple sclerosis. JAMA Neurol. 2019;76:866–867.
   PubMed Web of Science ®Google Scholar
• Dirks P, Zingler V, Leemhuis J, et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. BMC Neurol. 2020 Mar 14;20:95.
   PubMed Web of Science ®Google Scholar